Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/43192
Title: Multicenter comparison of Etest, Vitek2 and BD Phoenix to broth microdilution for beta-lactam susceptibility testing of Streptococcus pneumonia
Authors: Martens , Steven
Cuypers, Lize
Belik, Florian
Briers, Pieter-Jan
Ceyssens, Pieter-Jan
Denis, Olivier
Huang, Te-Din
MAGERMAN, Koen 
Strypens, Thomas
van den Abeele , Anne-Marie
DE SMET, Stefanie 
Issue Date: 2024
Publisher: SPRINGER
Source: European journal of clinical microbiology & infectious diseases (Print),
Status: Early view
Abstract: Purpose To assess performance of Etest (R), Vitek (R) 2 and BD Phoenix (TM) to determine the susceptibility of Streptococcus pneumoniae strains to penicillin, ampicillin and cefotaxime. Methods Sixty unique S. pneumoniae challenge strains were selected to cover a wide range of penicillin, ampicillin and cefotaxime minimal inhibitory concentrations (MICs). Strains were analyzed in four different Belgian laboratories. Etest (R) benzylpenicillin (BEN), ampicillin/amoxicillin (AMP) and cefotaxime (CTA) (bioM & eacute;rieux), Vitek (R) 2 AST-ST03 (bioM & eacute;rieux) and BD Phoenix (TM) SMIC/ID-11 testing were each performed in two different labs. Results were compared to Sensititre (R) broth microdilution (BMD) (Thermo Fisher Scientific) results. MIC results were interpreted using EUCAST non-meningitis breakpoints (v 13.0). Results Essential agreement (EA) was >= 90% for all methods compared to BMD, except for Etest (R) BEN on Oxoid plate (58.3%), Etest (R) AMP (both on Oxoid (65.8%) and BD BBL plate (84.2%)). Categorical agreement (CA) for penicillin was only >= 90% for Vitek (R) 2, for other methods CA ranged between 74 and 84%. CA for AMP was for all methods < 90% (range 75.8-88.3%) and CA for CTA was between 87 and 90% for all methods except for Etest on Oxoid plate (79.2%). Conclusions Our study indicates that Vitek (R) 2 and BD Phoenix (TM) are reliable for providing accurate pneumococcal susceptibility results for BEN, AMP and CTA. Using Etest BEN or AMP on Oxoid plate carries a risk of underestimating the MIC and should be interpreted with caution, especially when the obtained MIC is 1 or 2 doubling dilutions below the S or R clinical breakpoint.
Notes: Desmet, S (corresponding author), Univ Hosp Leuven, Natl Reference Ctr Invas Pneumococci, Herestr 49, B-3000 Leuven, Belgium.
stefanie.desmet@uzleuven.be
Keywords: Beta-lactam;Antimicrobial susceptibility testing;Streptococcus pneumoniae;EUCAST breakpoints
Document URI: http://hdl.handle.net/1942/43192
ISSN: 0934-9723
e-ISSN: 1435-4373
DOI: 10.1007/s10096-024-04847-2
ISI #: 001232224500004
Rights: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Category: A1
Type: Journal Contribution
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
s10096-024-04847-2.pdfEarly view1.25 MBAdobe PDFView/Open
Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.